Healthcare provider profile · identity verified

Ramya Korapati

Internal Medicine · NORTH GRAFTON, MA · NPI 1104122506

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	705	197
Lisinopril	Lisinopril	442	144
Amlodipine Besylate	Amlodipine Besylate	361	104
Levothyroxine Sodium	Levothyroxine Sodium	328	88
Omeprazole	Omeprazole	312	98
Hydrochlorothiazide	Hydrochlorothiazide	285	82
Simvastatin	Simvastatin	270	70
Metoprolol Succinate	Metoprolol Succinate	240	67
Losartan Potassium	Losartan Potassium	237	70
Potassium Chloride	Potassium Chloride	218	68
Rosuvastatin Calcium	Rosuvastatin Calcium	218	62
Eliquis	Apixaban	176	33
Metformin Hcl	Metformin Hcl	166	51
Sertraline Hcl	Sertraline Hcl	161	49
Furosemide	Furosemide	160	50
Gabapentin	Gabapentin	150	49
Warfarin Sodium	Warfarin Sodium	150	27
Lorazepam	Lorazepam	146	42
Albuterol Sulfate Hfa	Albuterol Sulfate	143	40
Famotidine	Famotidine	138	38
Tamsulosin Hcl	Tamsulosin Hcl	126	35
Atenolol	Atenolol	115	36
Trazodone Hcl	Trazodone Hcl	108	33
Valsartan	Valsartan	102	33
Allopurinol	Allopurinol	97	21
Nystatin	Nystatin	90	27
Fluticasone Propionate	Fluticasone Propionate	86	38
Pravastatin Sodium	Pravastatin Sodium	85	22
Montelukast Sodium	Montelukast Sodium	84	23
Metoprolol Tartrate	Metoprolol Tartrate	82	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	79	11
Mirtazapine	Mirtazapine	79	23
Pantoprazole Sodium	Pantoprazole Sodium	78	20
Torsemide	Torsemide	77	17
Alprazolam	Alprazolam	70	13
Oxycodone Hcl	Oxycodone Hcl	70	13
Spironolactone	Spironolactone	69	22
Carvedilol	Carvedilol	64	16
Citalopram Hbr	Citalopram Hydrobromide	62	15
Glipizide	Glipizide	60	14
Labetalol Hcl	Labetalol Hcl	58	18
Alendronate Sodium	Alendronate Sodium	57	17
Ibuprofen	Ibuprofen	56	22
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	56	34
Escitalopram Oxalate	Escitalopram Oxalate	48	15
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	45	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	45	27
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	42	29
Jardiance	Empagliflozin	41	13
Glipizide Er	Glipizide	40	12
Clonidine Hcl	Clonidine Hcl	38	suppressed
Klor-Con M20	Potassium Chloride	36	15
Ipratropium Bromide	Ipratropium Bromide	31	15
Tramadol Hcl	Tramadol Hcl	31	suppressed
Amoxicillin	Amoxicillin	30	19
Finasteride	Finasteride	30	suppressed
Metformin Hcl Er	Metformin Hcl	30	suppressed
Terazosin Hcl	Terazosin Hcl	29	11
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	29	suppressed
Estradiol	Estradiol	28	11
Lovastatin	Lovastatin	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Diazepam	Diazepam	27	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Ozempic	Semaglutide	27	suppressed
Meclizine Hcl	Meclizine Hcl	26	12
Pregabalin	Pregabalin	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Fenofibrate	Fenofibrate	25	suppressed
Lactated Ringers	Ringer's Solution,lactated	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	11
Prednisone	Prednisone	21	17
Clobetasol Propionate	Clobetasol Propionate	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	20	19
Klor-Con M10	Potassium Chloride	19	suppressed
Nadolol	Nadolol	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	15
Clonazepam	Clonazepam	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Temazepam	Temazepam	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Metronidazole	Metronidazole	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Azithromycin	Azithromycin	15	14
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Baclofen	Baclofen	14	suppressed
Cephalexin	Cephalexin	14	13
Chlorthalidone	Chlorthalidone	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error